Article Details
Retrieved on: 2022-07-25 10:23:50
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Hansa Biopharma AB, (Hansa), an enzyme technology for rare immunological conditions, secures $70 million in non-dilutive financing.
Article found on: www.businessleader.co.uk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here